Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 10;29:1611375. doi: 10.3389/pore.2023.1611375

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Ceglédi, Csukly, Fekete, Kozma, Szemlaky, Andrikovics and Mikala.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Time course of venetoclax therapy-induced changes in M protein in three myeloma patients. Sequential serum concentrations of M protein throughout the disease course are presented for three patients. Panels (A–C) depict the individual patients (patients 1, 2, and 3, respectively), showcasing the treatment type and duration (Patient #1 is treated for 24 months, patient #2 is treated for 12 months, patient #3 is treated for 6 months, therapies for patients #2 and #3 are currently ongoing, patient #1 is in treatment-free remission). Patient 3 results also include serial measurements of λ FLC to further demonstrate treatment response. VDT: Bortezomib, Dexamethasone, and Thalidomide; VD, Bortezomib, Dexamethasone; D, Dexamathasone; ASCT, Autologous Stem Cell Transplantation; Len, Lenalidomide; KD, Carfilzomib and Dexamethasone.